{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:59:32Z","timestamp":1774547972745,"version":"3.50.1"},"reference-count":81,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kimmel Foundation"},{"DOI":"10.13039\/501100001658","name":"Minerva Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001658","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ben May Professorial Chair"}],"content-domain":{"domain":["www.plosbiology.org"],"crossmark-restriction":false},"short-container-title":["PLoS Biol"],"abstract":"<jats:p>Nucleoside analogs are a major class of antiviral drugs. Some act by increasing the viral mutation rate causing lethal mutagenesis of the virus. Their mutagenic capacity, however, may lead to an evolutionary safety concern. We define evolutionary safety as a probabilistic assurance that the treatment will not generate an increased number of mutants. We develop a mathematical framework to estimate the total mutant load produced with and without mutagenic treatment. We predict rates of appearance of such virus mutants as a function of the timing of treatment and the immune competence of patients, employing realistic assumptions about the vulnerability of the viral genome and its potential to generate viable mutants. We focus on the case study of Molnupiravir, which is an FDA-approved treatment against Coronavirus Disease-2019 (COVID-19). We estimate that Molnupiravir is narrowly evolutionarily safe, subject to the current estimate of parameters. Evolutionary safety can be improved by restricting treatment with this drug to individuals with a low immunological clearance rate and, in future, by designing treatments that lead to a greater increase in mutation rate. We report a simple mathematical rule to determine the fold increase in mutation rate required to obtain evolutionary safety that is also applicable to other pathogen-treatment combinations.<\/jats:p>","DOI":"10.1371\/journal.pbio.3002214","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T17:30:02Z","timestamp":1691515802000},"page":"e3002214","update-policy":"https:\/\/doi.org\/10.1371\/journal.pbio.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Evolutionary safety of lethal mutagenesis driven by antiviral treatment"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7215-4111","authenticated-orcid":true,"given":"Gabriela","family":"Lobinska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3200-9344","authenticated-orcid":true,"given":"Yitzhak","family":"Pilpel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5489-0908","authenticated-orcid":true,"given":"Martin A.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"pbio.3002214.ref001","article-title":"Broad-spectrum antiviral strategies and nucleoside analogues.","author":"RJ Geraghty","year":"2021","journal-title":"Viruses"},{"key":"pbio.3002214.ref002","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijbiomac.2021.03.112","article-title":"A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase. International Journal of Biological Macromolecules","author":"S Khan","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"pbio.3002214.ref003","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19","volume":"19","author":"M Chien","year":"2020","journal-title":"J Proteome Res"},{"key":"pbio.3002214.ref004","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/BF00450633","article-title":"A principle of natural self-organization\u2014Part A: Emergence of the hypercycle","volume":"64","author":"M Eigen","year":"1977","journal-title":"Naturwissenschaften"},{"key":"pbio.3002214.ref005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0301-4622(82)87037-3","article-title":"Self-replication with errors. A model for polynucleotide replication","volume":"16","author":"J Swetina","year":"1982","journal-title":"Biophys Chem"},{"key":"pbio.3002214.ref006","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1063\/1.446590","article-title":"A localization threshold for macromolecular quasispecies from continuously distributed replication rates","volume":"80","author":"JS McCaskill","year":"1984","journal-title":"J Chem Phys"},{"key":"pbio.3002214.ref007","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0022-5193(89)80036-0","article-title":"Error thresholds of replication in finite populations mutation frequencies and the onset of Muller\u2019s ratchet","volume":"137","author":"MA Nowak","year":"1989","journal-title":"J Theor Biol"},{"key":"pbio.3002214.ref008","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/0169-5347(92)90145-2","article-title":"What is a quasispecies","volume":"7","author":"MA Nowak","year":"1992","journal-title":"Trends Ecol Evol"},{"key":"pbio.3002214.ref009","article-title":"Examining The Theory of Error Catastrophe","author":"J Summers","year":"2006","journal-title":"J Virol"},{"key":"pbio.3002214.ref010","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41598-018-19829-6","article-title":"Lethal mutagenesis of an RNA plant virus via lethal defection","volume":"8","author":"L D\u00edaz-Mart\u00ednez","year":"2018","journal-title":"Sci Rep"},{"key":"pbio.3002214.ref011","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1111\/evo.14107","article-title":"Imposed mutational meltdown as an antiviral strategy","volume":"74","author":"JD Jensen","year":"2020","journal-title":"Evolution"},{"key":"pbio.3002214.ref012","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"F Kabinger","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"pbio.3002214.ref013","first-page":"297","article-title":"Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template","author":"CJ Gordon","year":"2021","journal-title":"J Biol Chem"},{"key":"pbio.3002214.ref014","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells","volume":"224","author":"S Zhou","year":"2021","journal-title":"J Infect Dis"},{"key":"pbio.3002214.ref015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"P V\u2019kovski","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"pbio.3002214.ref016","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198504184.001.0001","volume-title":"Virus Dynamics: Mathematical Principles of Immunology And Virology.","author":"MA Nowak","year":"2000"},{"key":"pbio.3002214.ref017","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1128\/JVI.01624-06","article-title":"Theory of lethal mutagenesis for viruses","volume":"81","author":"JJ Bull","year":"2007","journal-title":"J Virol"},{"key":"pbio.3002214.ref018","first-page":"149","article-title":"The Molecular Quasi-Species","volume":"92","author":"M Eigen","year":"2007","journal-title":"J Phys Chem"},{"key":"pbio.3002214.ref019","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00002030-199805000-00006","article-title":"The frequency of resistant mutant virus before antiviral therapy","volume":"12","author":"RM Ribeiro","year":"1998","journal-title":"AIDS"},{"key":"pbio.3002214.ref020","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1073\/pnas.111085598","article-title":"RNA virus error catastrophe: Direct molecular test by using ribavirin","volume":"98","author":"S Crotty","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pbio.3002214.ref021","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00623322","article-title":"Selforganization of matter and the evolution of biological macromolecules","volume":"58","author":"M. Eigen","year":"1971","journal-title":"Naturwissenschaften"},{"key":"pbio.3002214.ref022","author":"M Eigen","year":"1992","journal-title":"Steps towards life: a perspective on evolution"},{"key":"pbio.3002214.ref023","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41562-021-01281-8","article-title":"Evolution of resistance to COVID-19 vaccination with dynamic social distancing","volume":"6","author":"G Lobinska","year":"2022","journal-title":"Nat Hum Behav"},{"key":"pbio.3002214.ref024","doi-asserted-by":"crossref","first-page":"204003","DOI":"10.1088\/1751-8121\/accda3","article-title":"Vaccination strategies in structured populations under partial immunity and reinfection","volume":"56","author":"G Rodriguez-Maroto","year":"2023","journal-title":"J Phys A Math Theor"},{"key":"pbio.3002214.ref025","article-title":"Diversity of vaccination-induced immune responses can prevent the spread of vaccine escape mutants","author":"JA Bouman","year":"2021","journal-title":"bioRxiv"},{"key":"pbio.3002214.ref026","doi-asserted-by":"crossref","first-page":"20220045","DOI":"10.1098\/rsif.2022.0045","article-title":"Vaccination strategies when vaccines are scarce: on conflicts between reducing the burden and avoiding the evolution of escape mutants","volume":"19","author":"F Geoffroy","year":"2022","journal-title":"J R Soc Interface"},{"key":"pbio.3002214.ref027","doi-asserted-by":"crossref","first-page":"e1010391","DOI":"10.1371\/journal.pcbi.1010391","article-title":"A spatial vaccination strategy to reduce the risk of vaccine-resistant variants.","volume":"18","author":"X Zhang","year":"2022","journal-title":"PLoS Comput Biol"},{"key":"pbio.3002214.ref028","article-title":"Effect of human behavior on the evolution of viral strains during an epidemic","author":"A Azizi","year":"2021","journal-title":"bioRxiv"},{"key":"pbio.3002214.ref029","first-page":"9","article-title":"Individual risk-aversion responses tune epidemics to critical transmissibility (R = 1).","author":"S Manrubia","year":"2022","journal-title":"R Soc Open Sci"},{"key":"pbio.3002214.ref030","article-title":"On the relationship between serial interval, infectiousness profile and generation time.","author":"S Lehtinen","year":"2021","journal-title":"J R Soc Interface"},{"key":"pbio.3002214.ref031","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.abd7343","article-title":"Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years","volume":"370","author":"CM Saad-Roy","year":"2020","journal-title":"Science (80-)."},{"key":"pbio.3002214.ref032","first-page":"eabg8663","article-title":"Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes","author":"CM Saad-Roy","year":"2021","journal-title":"Science (80-)."},{"key":"pbio.3002214.ref033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.63704","article-title":"Quantifying the impact of quarantine duration on COVID-19 transmission Peter","volume":"10","author":"P Ashcroft","year":"2021","journal-title":"Elife"},{"key":"pbio.3002214.ref034","first-page":"10","article-title":"Revisiting the guidelines for ending isolation for COVID-19 patients.","author":"YD Jeong","year":"2021","journal-title":"Elife"},{"key":"pbio.3002214.ref035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/978-1-4939-1115-8_30","article-title":"Mathematical models of HIV replication and pathogenesis","volume":"1184","author":"D. Wodarz","year":"2014","journal-title":"Methods Mol Biol"},{"key":"pbio.3002214.ref036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mbs.2005.09.003","article-title":"On the intra-host dynamics of HIV-1 infections","volume":"199","author":"NI Stilianakis","year":"2006","journal-title":"Math Biosci"},{"key":"pbio.3002214.ref037","doi-asserted-by":"crossref","first-page":"e1003568","DOI":"10.1371\/journal.pcbi.1003568","article-title":"Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study","volume":"10","author":"L Canini","year":"2014","journal-title":"PLoS Comput Biol"},{"key":"pbio.3002214.ref038","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1371\/journal.pcbi.0030240","article-title":"Neuraminidase Inhibitor Resistance in Influenza: Assessing the Danger of Its Generation and Spread","volume":"3","author":"A Handel","year":"2007","journal-title":"PLoS Comput Biol"},{"key":"pbio.3002214.ref039","first-page":"12","article-title":"Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms","author":"HM Dobrovolny","year":"2017","journal-title":"PLoS ONE"},{"key":"pbio.3002214.ref040","first-page":"13","article-title":"Understanding the within-host dynamics of influenza A virus: from theory to clinical implications","author":"C Hadjichrysanthou","year":"2016","journal-title":"J R Soc Interface"},{"key":"pbio.3002214.ref041","doi-asserted-by":"crossref","first-page":"e1000565","DOI":"10.1371\/journal.pcbi.1000565","article-title":"The Evolutionary Dynamics of a Rapidly Mutating Virus within and between Hosts: The Case of Hepatitis C Virus","volume":"5","author":"F Luciani","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"pbio.3002214.ref042","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"TP Sheahan","year":"2020","journal-title":"Sci Transl Med"},{"key":"pbio.3002214.ref043","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"RM Cox","year":"2021","journal-title":"Nat Microbiol"},{"key":"pbio.3002214.ref044","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"WA Fischer","year":"2022","journal-title":"Sci Transl Med"},{"key":"pbio.3002214.ref045","first-page":"1","article-title":"Phase 2\/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults","author":"Y Caraco","year":"2021","journal-title":"NEJM Evid."},{"key":"pbio.3002214.ref046","first-page":"1","article-title":"Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.","author":"JR Arribas","year":"2021","journal-title":"NEJM Evid"},{"key":"pbio.3002214.ref047","unstructured":"Merck and Ridgeback\u2019s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study\u2014Merck.com. [cited 2021 Nov 1]. Available from: https:\/\/www.merck.com\/news\/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat\/."},{"key":"pbio.3002214.ref048","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/jac\/dkab318","article-title":"Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study","volume":"76","author":"SH Khoo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"pbio.3002214.ref049","doi-asserted-by":"crossref","first-page":"100454","DOI":"10.1016\/j.epidem.2021.100454","article-title":"Estimation of the incubation period of COVID-19 using viral load data.","volume":"35","author":"K Ejima","year":"2021","journal-title":"Epidemics"},{"key":"pbio.3002214.ref050","doi-asserted-by":"crossref","first-page":"e2111477118","DOI":"10.1073\/pnas.2111477118","article-title":"In vivo kinetics of SARS-CoV-2 infection and its relationship with a person\u2019s infectiousness","volume":"118","author":"R Ke","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pbio.3002214.ref051","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host","volume":"383","author":"B Choi","year":"2020","journal-title":"N Engl J Med"},{"key":"pbio.3002214.ref052","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijid.2021.10.045","article-title":"COVID-19 in an immunocompromised host: persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations: a case report","volume":"114","author":"WF Leung","year":"2022","journal-title":"Int J Infect Dis"},{"key":"pbio.3002214.ref053","first-page":"1","article-title":"Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).","volume":"12","author":"JJA van Kampen","year":"2021","journal-title":"Nat Commun"},{"key":"pbio.3002214.ref054","first-page":"92","article-title":"Complexities of Viral Mutation Rates.","author":"KM Peck","year":"2018","journal-title":"J Virol"},{"key":"pbio.3002214.ref055","first-page":"9","article-title":"Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics.","author":"EC Smith","year":"2013","journal-title":"PLoS Pathog"},{"key":"pbio.3002214.ref056","doi-asserted-by":"crossref","first-page":"9733","DOI":"10.1128\/JVI.00694-10","article-title":"Viral Mutation Rates.","volume":"84","author":"R Sanju\u00e1n","year":"2010","journal-title":"J Virol"},{"key":"pbio.3002214.ref057","first-page":"9","article-title":"Sars-cov-2 (Covid-19) by the numbers","author":"YM Bar-On","year":"2020","journal-title":"Elife"},{"key":"pbio.3002214.ref058","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/emph\/eoac010","article-title":"Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution","volume":"10","author":"M Amicone","year":"2022","journal-title":"Evol Med Public Health"},{"key":"pbio.3002214.ref059","first-page":"4","article-title":"Experimentally guided models reveal replication principles that shape the mutation distribution of RNA viruses","author":"MB Schulte","year":"2015","journal-title":"Elife"},{"key":"pbio.3002214.ref060","first-page":"118","article-title":"The total number and mass of SARS-CoV-2 virions","author":"R Sender","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pbio.3002214.ref061","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0166-3542(02)00053-0","article-title":"The H274Y mutation in the influenza A\/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo","volume":"55","author":"JAL Ives","year":"2002","journal-title":"Antiviral Res"},{"key":"pbio.3002214.ref062","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/135965350400900404","article-title":"A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A\/H1N1 virus.","volume":"9","author":"Y Abed","year":"2004","journal-title":"Antivir Ther"},{"key":"pbio.3002214.ref063","first-page":"546","article-title":"Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations.","volume":"11","author":"S-Y Rhee","year":"2022","journal-title":"Pathog (Basel, Switzerland)."},{"key":"pbio.3002214.ref064","doi-asserted-by":"crossref","first-page":"e1010179","DOI":"10.1371\/journal.pgen.1010179","article-title":"Assessing in vivo mutation frequencies and creating a high-resolution genome-wide map of fitness costs of Hepatitis C virus","volume":"18","author":"KH Tisthammer","year":"2022","journal-title":"PLoS Genet"},{"key":"pbio.3002214.ref065","doi-asserted-by":"crossref","first-page":"8396","DOI":"10.1073\/pnas.0400146101","article-title":"The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus","volume":"101","author":"R Sanju\u00e1n","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pbio.3002214.ref066","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1098\/rstb.2010.0063","article-title":"Mutational fitness effects in RNA and single-stranded DNA viruses: common patterns revealed by site-directed mutagenesis studies","volume":"365","author":"R. Sanju\u00e1n","year":"2010","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"pbio.3002214.ref067","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding","volume":"182","author":"TN Starr","year":"2020","journal-title":"Cell"},{"key":"pbio.3002214.ref068","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"TN Starr","year":"2021","journal-title":"Science (80-)."},{"key":"pbio.3002214.ref069","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1063\/1.1378322","article-title":"Approximate accelerated stochastic simulation of chemically reacting systems","volume":"115","author":"DT Gillespie","year":"2001","journal-title":"J Chem Phys"},{"key":"pbio.3002214.ref070","first-page":"12","article-title":"Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing","author":"C Kern","year":"2021","journal-title":"Front Pharmacol"},{"key":"pbio.3002214.ref071","doi-asserted-by":"crossref","first-page":"e3001128","DOI":"10.1371\/journal.pbio.3001128","article-title":"A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2","volume":"19","author":"KS Kim","year":"2021","journal-title":"PLoS Biol"},{"key":"pbio.3002214.ref072","first-page":"8","article-title":"Estimation of viral kinetics model parameters in young and aged SARS-CoV-2 infected macaques.","author":"T Rodriguez","year":"2021","journal-title":"R Soc Open Sci"},{"key":"pbio.3002214.ref073","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41591-022-01780-9","article-title":"Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults","volume":"28","author":"B Killingley","year":"2022","journal-title":"Nat Med"},{"key":"pbio.3002214.ref074","doi-asserted-by":"crossref","first-page":"e2017962118","DOI":"10.1073\/pnas.2017962118","article-title":"Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort","volume":"118","author":"N N\u00e9ant","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pbio.3002214.ref075","first-page":"40","article-title":"Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China","author":"Y Wang","year":"2021","journal-title":"eClinicalMedicine"},{"key":"pbio.3002214.ref076","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ijid.2021.05.062","article-title":"Modeling the early temporal dynamics of viral load in respiratory tract specimens of COVID-19 patients in Incheon, the Republic of Korea","volume":"108","author":"AY Lim","year":"2021","journal-title":"Int J Infect Dis"},{"key":"pbio.3002214.ref077","doi-asserted-by":"crossref","DOI":"10.1126\/science.abi5273","article-title":"Estimating infectiousness throughout SARS-CoV-2 infection course","volume":"373","author":"TC Jones","year":"2021","journal-title":"Science (80-)."},{"key":"pbio.3002214.ref078","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"X He","year":"2020","journal-title":"Nat Med"},{"key":"pbio.3002214.ref079","doi-asserted-by":"crossref","first-page":"e0243597","DOI":"10.1371\/journal.pone.0243597","article-title":"Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients.","volume":"15","author":"H Kawasuji","year":"2020","journal-title":"PLoS ONE"},{"key":"pbio.3002214.ref080","first-page":"373","article-title":"Estimating epidemiologic dynamics from cross-sectional viral load distributions","author":"JA Hay","year":"2021","journal-title":"Science (80-)."},{"key":"pbio.3002214.ref081","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"A Shannon","year":"2020","journal-title":"Nat Commun"}],"container-title":["PLOS Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3002214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:00:52Z","timestamp":1702922452000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3002214"}},"subtitle":[],"editor":[{"given":"Andrew Fraser","family":"Read","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":81,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pbio.3002214","relation":{},"ISSN":["1545-7885"],"issn-type":[{"value":"1545-7885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]}}}